Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

An observational study to assess persistence, adherence, quality of life, and treatment satisfaction in patients beginning therapy with the Avonex® PEN™ (PERSIST)
Bullous pemphigoid in a patient with multiple sclerosis being treated with human immunoglobulin.
High dose naltrexone for dyskinesias induced by levodopa.
Sanofi sees US FDA ruling for MS drug Lemtrada in Q4
[Budget impact analysis of the first-line treatment of relapsing remitting multiple sclerosis in Spain. Reply].
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
The little compound that could: how phenytoin changed drug discovery and development.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
The risk of multiple sclerosis in bereaved parents: A nationwide cohort study in Denmark.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
Periventricular lesions help differentiate neuromyelitis optica spectrum disorders from multiple sclerosis.
Effects of exercise in experimental autoimmune encephalomyelitis (an animal model of multiple sclerosis).
Phase IV Study Reports Multiple Sclerosis Success with Teriflunomide
[Diagnosis of multiple sclerosis - the 2010 revision of the McDonald criteria.]
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Safety Study of RTL1000 (Recombinant T Cell Receptor Ligand) in Subjects with Multiple Sclerosis
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
High dose thiamine improves fatigue in multiple sclerosis.
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
Vision in a Phase 3 Trial of Natalizumab for Multiple Sclerosis: Relation to Disability and Quality of Life.
Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis.
Treatment of walking impairment in multiple sclerosis with dalfampridine.
Medicare Part D payments for neurologist-prescribed drugs.

Pages